Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 3 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 3 W ELECTROLYTES.
FREAMINE II 8.5% vs FREAMINE III 3% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting nitrogen balance and tissue repair in patients unable to tolerate oral or enteral nutrition.
Provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions. Electrolytes help maintain acid-base balance and osmotic pressure.
Intravenous infusion: 0.8-1.5 g amino acids/kg/day. Typical dose is 500-1000 mL per day (42.5-85 g amino acids). Infusion rate should not exceed 0.1 g amino acids/kg/hour.
Administered intravenously. Typical adult dose: 500-1000 mL/day (15-30 g amino acids) infused at a rate not exceeding 0.1 g/kg/hour. Frequency: continuous or intermittent infusion as part of parenteral nutrition.
None Documented
None Documented
Not applicable as a mixture; individual amino acids have variable half-lives (e.g., essential amino acids ~1-3 hours). Clinical context: continuous infusion required to maintain plasma levels.
Variable; based on individual amino acid components (alanine ~2.3h, glycine ~1.5h, etc.); clinical context: continuous infusion achieves steady state within 8-12h
Renal elimination of nitrogenous waste products (urea) derived from amino acid metabolism; <5% excreted unchanged in urine. No significant biliary or fecal elimination.
Renal excretion of amino acid nitrogen as urea (85-90%) and other nitrogenous wastes; minimal biliary/fecal (<5%)
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid